ARW ON RNA
"Ghosts Of mRNA Past & Present": 6 RNA/LNP Execs Revisit 2024
But much like Dicken's “A Christmas Carol” with its emphasis on how the past and present inform the future, I was struck by six RNA executive’s appreciation for where we have been and currently are as an industry, and how these moments in time are already informing mRNA/RNA’s bright future.
OUR EXPERT NETWORK
-
![FDA headquarter iStock-1213293784]( "FDA Issues New Guidance: Nonclinical Safety Assessment Of Oligonucleotide-Based Therapeutics")
FDA Issues New Guidance: Nonclinical Safety Assessment Of Oligonucleotide-Based TherapeuticsFDA's CDER recently issued a draft guidance: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. This article provides a summary and analysis. The public comment period ends January 14, 2025.
-
![Artificial Intelligence, AI-GettyImages-2178269161]( "Is Your CDMO Using These AI-Driven Solutions In CMC For Oligos And Peptides?")
Is Your CDMO Using These AI-Driven Solutions In CMC For Oligos And Peptides?Oligonucleotides and peptides require precise, scalable, and compliant production. CDMOs are integrating AI-driven technologies to answer the call. Many of these technologies are notable for specific needs.
-
![DNA RNA editing-GettyImages-1398567874]( "RNase Control: An Overview With Market Trends")
RNase Control: An Overview With Market TrendsThis article shares an overview of ribonuclease (RNase) control and some associated macro market research.
-
![GettyImages-1295693748-mRNA]( "Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases")
Developing Bespoke Antisense Oligonucleotides To Treat Rare DiseasesEveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.
-
![Cell transfection with plasmid GettyImages-1290924802]( "Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why")
Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's WhyThe demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.
WEBINARS
MEET ARW
I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
ARW ON BUSINESS OF BIOTECH
-
![24_01_BoB_1280x720_Ep217]( "Pivoting To RNA With Circio's Dr. Erik Digman Wiklund")
This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.
-
![24_01_BoB_1280x720_Ep216]( "mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D.")
Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception.
-
![24_01_BoB_1280x720_Ep199]( "Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch")
As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O", RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.
VIRTUAL EVENTS
- Achieving Next-Generation mRNA-LNP Therapeutics Delivery
- From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain
- Can We Do Better? Current & Future Realities of mRNA Process Development
- Opening The "Black Box" Of The mRNA Regulatory Paradigm
- Got Raw Materials? The State Of The mRNA Supply Chain
- mRNA For Cancer Immunotherapy: 2024 Outlook
NEWSLETTER ARCHIVE
- 12.12.24 -- How To Ensure 21 CFR Part 11 Compliance
- 12.12.24 -- All Eyes On Sustainability
- 12.11.24 -- Pushing Drug Development Forward With mRNA Expertise
- 12.11.24 -- Navigating the "Holy Trinity" of RNA Structure, Process, & Biology
- 12.04.24 -- How Platform Technologies Are Shaping The Gene Therapy Landscape
- 11.27.24 -- Tackling Standardization For mRNA Therapeutics